Literature DB >> 24477207

IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia?

C W Redman1, I L Sargent2, A C Staff3.   

Abstract

Incomplete spiral artery remodelling is the first of two stages of pre-eclampsia, typically of early onset. The second stage comprises dysregulated uteroplacental perfusion and placental oxidative stress. Oxidatively stressed syncytiotrophoblast (STB) over-secretes proteins that perturb maternal angiogenic balance and are considered to be pre-eclampsia biomarkers. We propose that, in addition and more fundamentally, these STB-derived proteins are biomarkers of a cellular (STB) stress response, which typically involves up-regulation of some proteins and down-regulation of others (positive and negative stress proteins respectively). Soluble vascular growth factor receptor-1 (sVEGFR-1) and reduced growth factor (PlGF) then exemplify positive and negative STB stress response proteins in the maternal circulation. Uncomplicated term pregnancy is associated with increasing sVEGFR-1 and decreasing PlGF, which can be interpreted as evidence of increasing STB stress. STB pathology, at or after term (for example focal STB necrosis) demonstrates this stress, with or without pre-eclampsia. We review the evidence that when placental growth reaches its limits at term, terminal villi become over-crowded with diminished intervillous pore size impeding intervillous perfusion with increasing intervillous hypoxia and STB stress. This type of STB stress has no antecedent pathology, so the fetuses are well-grown, as typifies late onset pre-eclampsia, and prediction is less effective than for the early onset syndrome because STB stress is a late event. In summary, abnormal placental perfusion and STB stress contribute to the pathogenesis of early and late onset pre-eclampsia. But the former has an extrinsic cause - poor placentation, whereas the latter has an intrinsic cause, 'microvillous overcrowding', as placental growth reaches its functional limits. This model explains important features of late pre-eclampsia and raises questions of how antecedent medical risk factors such as chronic hypertension affect early and late sub-types of the syndrome. It also implies that all pregnant women may be destined to get pre-eclampsia but spontaneous or induced delivery averts this outcome in most instances.
Copyright © 2013 IFPA and Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Early onset pre-eclampsia; Integrated stress response; Late onset pre-eclampsia; Placental perfusion; Pre-eclampsia biomarkers; Syncytiotrophoblast stress response

Mesh:

Substances:

Year:  2014        PMID: 24477207     DOI: 10.1016/j.placenta.2013.12.008

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  132 in total

1.  Increased circulating levels of Epidermal Growth Factor-like Domain 7 in pregnant women affected by preeclampsia.

Authors:  Micol Massimiani; Lauretta A Lacko; Clare S Burke Swanson; Silvia Salvi; Lissenya B Argueta; Sascia Moresi; Sergio Ferrazzani; Shari E Gelber; Rebecca N Baergen; Nicola Toschi; Luisa Campagnolo; Heidi Stuhlmann
Journal:  Transl Res       Date:  2018-12-25       Impact factor: 7.012

2.  The RNA landscape of the human placenta in health and disease.

Authors:  Gordon C S Smith; D Stephen Charnock-Jones; Sungsam Gong; Francesca Gaccioli; Justyna Dopierala; Ulla Sovio; Emma Cook; Pieter-Jan Volders; Lennart Martens; Paul D W Kirk; Sylvia Richardson
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

3.  Evolutionary origins of the placental expression of chromosome 19 cluster galectins and their complex dysregulation in preeclampsia.

Authors:  N G Than; R Romero; Y Xu; O Erez; Z Xu; G Bhatti; R Leavitt; T H Chung; H El-Azzamy; C LaJeunesse; B Wang; A Balogh; G Szalai; S Land; Z Dong; S S Hassan; T Chaiworapongsa; M Krispin; C J Kim; A L Tarca; Z Papp; H Bohn
Journal:  Placenta       Date:  2014-08-26       Impact factor: 3.481

Review 4.  A best practice position statement on the role of the nephrologist in the prevention and follow-up of preeclampsia: the Italian study group on kidney and pregnancy.

Authors:  Giorgina Barbara Piccoli; Gianfranca Cabiddu; Santina Castellino; Giuseppe Gernone; Domenico Santoro; Gabriella Moroni; Donatella Spotti; Franca Giacchino; Rossella Attini; Monica Limardo; Stefania Maxia; Antioco Fois; Linda Gammaro; Tullia Todros
Journal:  J Nephrol       Date:  2017-04-22       Impact factor: 3.902

Review 5.  A potential pathophysiological role for galectins and the renin-angiotensin system in preeclampsia.

Authors:  Sandra M Blois; Ralf Dechend; Gabriela Barrientos; Anne Cathrine Staff
Journal:  Cell Mol Life Sci       Date:  2014-09-06       Impact factor: 9.261

Review 6.  Evidence for Corpus Luteal and Endometrial Origins of Adverse Pregnancy Outcomes in Women Conceiving with or Without Assisted Reproduction.

Authors:  Kirk P Conrad
Journal:  Obstet Gynecol Clin North Am       Date:  2020-03       Impact factor: 2.844

7.  Extracellular vesicles generated by placental tissues ex vivo: A transport system for immune mediators and growth factors.

Authors:  Wendy Fitzgerald; Nardhy Gomez-Lopez; Offer Erez; Roberto Romero; Leonid Margolis
Journal:  Am J Reprod Immunol       Date:  2018-05-04       Impact factor: 3.886

8.  Nanoparticle mediated increased insulin-like growth factor 1 expression enhances human placenta syncytium function.

Authors:  Rebecca L Wilson; Kathryn Owens; Emily K Sumser; Matthew V Fry; Kendal K Stephens; Marcel Chuecos; Maira Carrillo; Natalia Schlabritz-Loutsevitch; Helen N Jones
Journal:  Placenta       Date:  2020-02-12       Impact factor: 3.481

9.  Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice.

Authors:  Jeremy A Sandgren; Guorui Deng; Danny W Linggonegoro; Sabrina M Scroggins; Katherine J Perschbacher; Anand R Nair; Taryn E Nishimura; Shao Yang Zhang; Larry N Agbor; Jing Wu; Henry L Keen; Meghan C Naber; Nicole A Pearson; Kathy A Zimmerman; Robert M Weiss; Noelle C Bowdler; Yuriy M Usachev; Donna A Santillan; Matthew J Potthoff; Gary L Pierce; Katherine N Gibson-Corley; Curt D Sigmund; Mark K Santillan; Justin L Grobe
Journal:  JCI Insight       Date:  2018-10-04

10.  Proteomic identification of Placental Protein 1 (PP1), PP8, and PP22 and characterization of their placental expression in healthy pregnancies and in preeclampsia.

Authors:  Szilvia Szabo; Katalin Karaszi; Roberto Romero; Eszter Toth; Andras Szilagyi; Zsolt Gelencser; Yi Xu; Andrea Balogh; Gabor Szalai; Petronella Hupuczi; Beata Hargitai; Tibor Krenacs; Eva Hunyadi-Gulyas; Zsuzsanna Darula; Katalin A Kekesi; Adi L Tarca; Offer Erez; Gabor Juhasz; Ilona Kovalszky; Zoltan Papp; Nandor Gabor Than
Journal:  Placenta       Date:  2020-06-22       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.